According to a new report by Polaris Market Research, the global Tremfya market was valued at USD 4.2 billion in 2025 and is projected to reach USD 7.99 billion by 2034, expanding at a CAGR of 7.40% over the forecast period. Growth is underpinned by rising adoption of biologic therapies, expanding regulatory approvals across inflammatory indications, and accelerating investment in immunology research across key end-use markets.
What Is Driving Tremfya Market Growth?
Demand is climbing as the growing burden of chronic plaque psoriasis and psoriatic arthritis converges with a broader shift toward targeted biologic treatment over traditional systemic therapies. Dermatologists and rheumatologists are increasingly prioritizing IL-23 pathway inhibition, pushing Tremfya adoption across specialty care settings worldwide. Polaris analysts note that expanding label indications into ulcerative colitis and Crohn's disease position the drug for sustained growth through 2034, with plaque psoriasis remaining the largest revenue contributor and psoriatic arthritis posting the fastest incremental gains.
Key Trends Shaping the Tremfya Industry
Oral Biologic Innovation Expands the Pipeline
Johnson & Johnson's investigational oral IL-23 receptor antagonist, JNJ-2113, is advancing through Phase 3 trials for plaque psoriasis and has shown strong skin-clearance results in earlier-stage studies. A needle-free follow-on option could reshape patient preference and broaden treatment access, supporting continued product innovation in the category.
Regulatory Label Expansions Widen the Addressable Market
Regulatory approvals extending Tremfya's use into moderately to severely active ulcerative colitis and Crohn's disease have broadened its addressable patient population beyond dermatology and rheumatology. This shift in the regulatory landscape strengthens the drug's position across gastroenterology and reinforces demand from a wider specialist base.
Biosimilar Pressure Shapes the Competitive Outlook
With patent expiry approaching, emerging biopharmaceutical companies are advancing IL-23 inhibitor biosimilars, intensifying long-term pricing pressure. This competitive landscape shift is prompting continued investment in real-world evidence and patient support programs to protect market share ahead of biosimilar entry.
Market Segmentation: Breaking Down the Tremfya Market
Polaris segments the Tremfya market by application, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.
By Application
The plaque psoriasis segment led the market in 2025, accounting for 85.31% of revenue, reflecting the disease's high global prevalence and Tremfya's established efficacy in clearing skin lesions. The psoriatic arthritis (PsA) segment is projected to expand at the fastest rate through 2034 as diagnosis rates rise and clinical evidence of its joint-damage benefit continues to build.
By Distribution Channel
Hospital pharmacies captured 51.52% of revenue in 2025, driven by the specialized handling, storage, and administration requirements of biologic therapies. Online pharmacies are gaining share the fastest, signaling where near-term demand — and search intent around specialty drug delivery — is shifting as telehealth and cold-chain logistics improve.
Regional Outlook: Where Is Tremfya Growing Fastest?
North America led the market in 2025 on the back of high chronic-disease prevalence and mature biologics infrastructure, while Asia Pacific is expected to post the fastest CAGR of 10.8% through 2034, driven by rising healthcare investment and improving diagnosis rates. Within North America, the U.S. remains the largest single market, commanding 83.12% of regional revenue; within Asia Pacific, Japan is a primary growth engine given its advanced healthcare system and streamlined drug-approval pathway. Europe rounds out the top three, supported by expanding EMA-approved indications and strong reimbursement frameworks in markets such as Germany.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :
https://www.polarismarketresearch.com/industry-analysis/tremfya-market
Competitive Landscape: Leading Tremfya Companies
Johnson & Johnson remains the dominant player profiled in the report, leveraging its immunology expertise, established prescriber relationships, and continued label expansion to strengthen its position across the plaque psoriasis and psoriatic arthritis segments outlined above. Recent moves include a May 2026 FDA label expansion confirming Tremfya as the only IL-23 inhibitor shown to slow joint-damage progression in active psoriatic arthritis, alongside an earlier approval for Crohn's disease, both aimed at deepening its footprint across North America and Europe. Emerging biosimilar developers, including Bio-Thera Solutions, Alvotech, and Samsung Bioepis, are also advancing IL-23 inhibitor candidates ahead of patent expiry.
Why It Matters for Buyers Evaluating the Immunology Market
For stakeholders researching the Tremfya market forecast, this report benchmarks market share, segment-level data, and forecast figures — by application, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing specialty suppliers, investors sizing entry points in immunology, and strategy teams tracking psoriatic arthritis as a growth adjacency within the broader biologics landscape.
More Trending Latest Reports By Polaris Market Research: